Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | LCK | P06239 | 3/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 2/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26127114 | 0.94 | IRAK4 (0.35) | IRAK4PAX8CCR1CCR8TGFBR1 | |
| SCHEMBL30580939 | 0.79 | GSTO1 (0.40) | IRAK4PAX8CCR1CCR8USP30 | |
| SCHEMBL123769 | 0.77 | USP30 (0.33) | PAX8LCKUSP30 | |
| SCHEMBL26127116 | 0.74 | TGFBR1 (0.37) | CCR1CCR8TGFBR1GRM5LCK | |
| SCHEMBL26124547 | 0.74 | GSTO1 (0.41) | IRAK4PAX8CCR1CCR8USP30 | |
| SCHEMBL959885 | 0.73 | GRM5 (0.38) | IRAK4PAX8CCR1CCR8TGFBR1 | |
| SCHEMBL23113073 | 0.72 | PAX8 (0.40) | PAX8LCKRAB9A | |
| SCHEMBL14551211 | 0.71 | RAB9A (0.37) | IRAK4CCR1CCR8GRM5RAB9A | |
| SCHEMBL31733296 | 0.71 | MAPT (0.47) | PAX8RAB9A | |
| SCHEMBL2171106 | 0.71 | MAPT (0.47) | PAX8RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206730-A1 | THIAZOLE DERIVATIVE COMPOUND AND USES THEREOF | AUTOTELIC BIO INC. (KR) | 2025-06-26 | — | — | US | disclosed |
| WO-2025063819-A1 | COMPOSITION FOR TREATING FIBROTIC DISEASE COMPRISING THIAZOLE DERIVATIVE COMPOUND | 오토텔릭바이오 주식회사 | 2025-03-27 | — | — | WO | disclosed |
| WO-2025063820-A1 | COMPOSITION FOR TREATING PULMONARY FIBROSIS COMPRISING THIAZOLE DERIVATIVE COMPOUND | 오토텔릭바이오 주식회사 | 2025-03-27 | — | — | WO | disclosed |
| WO-2025063816-A1 | COMPOSITION FOR TREATING UTERINE FIBROSIS COMPRISING THIAZOLE DERIVATIVE COMPOUND | 오토텔릭바이오 주식회사 | 2025-03-27 | — | — | WO | disclosed |
| EP-4501928-A1 | THIAZOLE DERIVATIVE COMPOUND AND USES THEREOF | Autotelic Bio Inc. (KR) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023182780-A1 | THIAZOLE DERIVATIVE COMPOUND AND USES THEREOF | 오토텔릭바이오 주식회사 | 2023-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206730-A1 | THIAZOLE DERIVATIVE COMPOUND AND USES THEREOF | TGFBR1, TGFBR2, ALK | IRAK4 51/4885PAX8 3424/4885CCR1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.